• murdock creative

Kitov Pharma Climbing a Successful Summit in July/August

Updated: Jun 30

Kitov Pharma has been focusing on its cancer therapy NT219 as a therapy for multiple treatment-resistant cancers.

Kitov Pharma Climbing a Successful Summit in June


Kitov Pharma Nasdaq:KTOV, stock has begun to attract investors and share holders with incoming PR of a strategic partnership and collaboration with another leading company focusing on its cancer therapy NT219 as a therapy for multiple treatment-resistant cancers. Not to forget the launch of non-steroidal anti-inflammatory drug Consensi, for the treatment of pain caused by osteoarthritis, and amlodipine besylate, a drug designed to treat hypertension. This stock is the stock to watch this week!


I began watching this penny stock with interest and started my journey with KTOV when following tips from yates investing and stan the man on Twitter. Kitov Pharma shares were trading at $0.45 when I began investing and researching into the background of this company.


NT-219 Collaboration agreement with potential strategic partner.


© 2020 by Murdock Creative Investments. Proudly designed by Murdock Creative.